Salute e Benessere

Excellent 12-Month Results from SELUTION SFA Trial Presented at JET

"These data demonstrate that limus can be as effective as paclitaxel without the associated safety concerns and welcomes a new era for DCB,", said Dr. Osamu Iida, Osaka Police Hospital Cardiovascular Center, Osaka, Japan. "These data demonstrate that limus can be as effective as paclitaxel without the associated safety concerns and welcomes a new era for DCB,", said Dr.Osamu Iida,OsakaPolice Hospital Cardiovascular Center,Osaka, Japan. "I loved Dr Iida's comment, 'if…
PR Newswire
31/05/2023

SNIPR Biome reports positive clinical interim results for groundbreaking…

These findings demonstrate clinical proof of principle for this new technology, and future studies are now being planned to evaluate the impact of SNIPR001 on reducing the rate of infections in cancer patients at high risk of E. coli gut translocation into the bloodstream. SNIPR001 has the potential to prevent life-threatening bloodstream infections in over 35,000 cancer patients annually across the United States and Europe. In addition, the Phase 1 results support development of an…
PR Newswire
31/05/2023

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and…

"We are excited to provide biological storage to QUALIblood, and its partners, to advance research, develop innovative solutions, and support the scientific community's efforts to improve healthcare outcomes," said Stephen Delaney, Managing Director at Q1 Scientific. "This partnership fills a significant gap in the Belgium and broader European biobanking ecosystem, where there is a growing demand for secure and reliable storage solutions for biological samples." "We are…
PR Newswire
31/05/2023

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug…

Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen our anticancer drug pipeline in the future." Yuhan Corporation CEO, Wook-Je Cho said, "We have taken a step forward in the development of the 2nd and 3rd LECLAZA by securing an additional anti-cancer drug pipeline with this contract. We plan to further strengthen…
PR Newswire
31/05/2023

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

Saint-Herblain (France) ,May31 , 2023–ValnevaSE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will attend the Jefferies Healthcare Conference (June 7-9 in New York), Goldman Sachs Annual Global Healthcare Conference (June 12-15 in Dana Point, California) and the Stifel European Healthcare Conference (June 28-30 in Bordeaux, France).Valneva will present and meet with institutional investors to discuss the...
Nasdaq GlobeNewswire
31/05/2023

Kinarus Therapeutics Group Reports 2022 Annual Results

Publishes Annual Report with Audited Consolidated Financial Results for Year Ended 31 December 2022Clinical efforts re-focused on developing KIN001 for original indications IPF and wet AMDCDIM CHF1.5 million convertible loan agreement supports Chinese partnering Basel, Switzerland , 31May 2023 .Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...
Nasdaq GlobeNewswire
31/05/2023

Valneva Announces the Availability of Documentation for its Shareholder Meeting

Saint-Herblain (France) , May31 , 2023–ValnevaSE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon (France).The preliminary Notice of Meeting, containing the agenda, the draft resolutions and instructions for participation and voting, was...
Nasdaq GlobeNewswire
31/05/2023

Ipsen - Description of the regulatory framework of the share repurchase program…

REGULATED INFORMATION Description of the regulatory framework of the share repurchase program proposed by the Boardof Directors to be approved at the Combined Shareholders' Meeting on 31 May 2023 (15 thresolution)Boulogne-Billancourt (France), on 31 May 2023- In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014, the...
Nasdaq GlobeNewswire
31/05/2023

Press Release: Positive Phase 2 data of novel investigational anti-CD40L…

Positive Phase 2 data of novelinvestigational anti-CD40Lantibody frexalimabshowsignificantly reduced disease activity in relapsing multiple sclerosisFrexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placeboSanofi plans to initiate pivotal trials in multiple sclerosis in early 2024Paris , May31 2023 .New data, being...
Nasdaq GlobeNewswire
31/05/2023

Bluebell Group releases "2023 Asia Lifestyle Consumer Profile"

This year, three core trends have emerged in our study: This year, three core trends have emerged in our study: Trend 1 - 'Safe' luxury: after the storm, consumers find a new comfort zone Figures suggest a resurgence of 'traditional' attitudes toward luxury, including the status that it represents, the importance placed on a brand's reputation, and expectations on service. But markets show distinct comfort zones when it comes to shopping pre-owned, local and niche. "During the...
PR Newswire
31/05/2023

Merck Increases Global Commitment to Biosafety Testing With € 35 Million…

The centerpiece of the investment is a new, 1,200-square-meter facility in Glasgow, which will house molecular biology and sequencing services. The company will expand testing capacity in its current buildings with biosafety testing, analytical development, and viral clearance suites. The latest investment follows the company's recent Rockville, Maryland, USA, and Shanghai, China testing expansions. The centerpiece of the investment is a new, 1,200-square-meter facility inGlasgow, which will...
PR Newswire
31/05/2023

Brain-computer interface to control digital devices using thoughts: The European…

Oxley is a vascular and interventional neurologist and an expert in brain-computer interfaces, and Opie is a biomedical engineer and expert in neural interfaces. Oxley and Opie's collaboration led to the founding of Synchron in 2016, a company specialising in developing implantable neural interfaces for the treatment of neurological disorders. The pair's commitment to patients and combined expertise paved the way to the Stentrode. For the 14 million people worldwide living with neuromuscular…
PR Newswire
30/05/2023

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic…
PR Newswire
30/05/2023

eureKING, the first European SPAC in healthcare dedicated to biomanufacturing…

Skyepharma is a France-based CDMO with over 20 years of innovation and development expertise and a renowned player in the global biopharma and consumer health industries. The company's unique offer in the biomanufacturing process spans all stages of clinical development, marketing and product lifecycleThe proposed transaction would value Skyepharma at an enterprise value ofcirca. €50 million and an equity value ofcirca. €52 million.eureKING would ...
Nasdaq GlobeNewswire
30/05/2023

Vistin Pharma ASA: Mandatory notification of trade

Ferncliff Listed DAI AS has on 30 May 2023 purchased 250,000 shares in Vistin Pharma ASA at NOK 23.12 per share. After the transaction Ferncliff Listed DAI AS has a holding of 1,034,280 shares, corresponding to 2,33% ownership. Ferncliff Listed DAI AS are closely associated with board member Øystein Stray Spetalen. Attachment 20230530_Notification of trade_Ferncliff i Vistin
Nasdaq GlobeNewswire
30/05/2023

Change in management

The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.Anders Fink Vadsholt states:”With the latest progress in our US security class...
Nasdaq GlobeNewswire
30/05/2023

Live Cell Imaging Market worth $4.3 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483 Browse in-depth TOC on "Live Cell Imaging Market" 293 - Tables 50 - Figures 305 - Pages Live Cell Imaging Market Scope: The cell biology segment accounted for the largest share, by application in the live cell imaging market in 2022. By application, the...
PR Newswire
30/05/2023

Pettenon Cosmetics Selects Centric PLM to Streamline Product Development

For more than 70 years, Pettenon Cosmetics Spa SB has been supporting high-quality Italian Professional Hair Care in Italy and worldwide. They offer premium products that can be customized to meet specific market needs and suit different hair types and conditions. Pettenon Cosmetics Spa SB boasts an impressive sales network spanning 91 countries across the globe and produces 170,000 items every day, including shampoo, masks, styling products, hydrogen peroxide and other technical goods. For...
PR Newswire
30/05/2023

Sexual Health Supplement Market to Experience Robust Growth of More than $4…

Browse In-Depth TOC of the Sexual Health Supplement Market Browse In-Depth TOC of the Sexual Health Supplement Market 129 - Tables 126 - Charts 281–Pages Sexual health, a vital aspect of overall well-being, has become a hot topic in the healthcare industry. With numerous factors wreaking havoc on the intimate lives of men and women, issues like erectile dysfunction and infertility are making headlines. It's a global concern, folks! Sexual problems are sneaky...
PR Newswire
30/05/2023

Air Purifying Respirators Market Size Will Attain USD 3854.11 Million by 2028…

Air Purifying Respirators Market: Overview Air Purifying Respirators Market: Overview A type of personal protection equipment (PPE) called an air-purifying respirator is used by employees in environments where the air is contaminated by fumes, dust, odors, hazardous gases, or vapors. Through face masks and hoods, an air-purifying respirator offers clean, breathable air that helps to remove air contaminants. Numerous viral health risks are on the rise, and the recent COVID-19 pandemic...
PR Newswire
30/05/2023

Parkinson's Disease Market to Exhibit Growth at a CAGR of 11.2% During the Study…

Key Takeaways from the Parkinson's Disease Market Report Key Takeaways from the Parkinson's Disease Market Report Discover which therapies are expected to grab the major Parkinson's disease market share @Parkinson's Disease Market Report Parkinson's Disease Overview Parkinson's disease is a degenerative ailment caused by the loss of nerve cells in the substantia nigra, a region of the brain that governs movement. The cause of Parkinson's disease is unknown, however, it has...
PR Newswire
30/05/2023

Transactions in connection with share buy-back program

Company announcement no. 22 - 2330 May 2023 Transactions in connection with share buy-back program On 8 May 2023 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company announcement no. 17 - 23. The program will be executed in accordance with the principles of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbor rules...
Nasdaq GlobeNewswire
30/05/2023

Optical Coherence Tomography (OCT) Market to Grow Substantially by 2029 -…

Key Takeaways Key Takeaways The Optical Coherence Tomography (OCT) Market is anticipated to generate significant returns over the analysis timeline of 2022-2029. Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/285 Elaborating the Key Trends and Dynamics of Optical Coherence Tomography (OCT) Market Growing prevalence of ocular diseases, surge in the geriatric population base, along with the escalating demand for early disease diagnosis and...
PR Newswire
30/05/2023

Wireless Brain Sensor Market to Grow Exponentially by 2029- Brandessence Market…

Key Takeaways Key Takeaways The Wireless Brain Sensor Market is expected to grow substantially over the forecast duration of 2022-2029. Get Sample of Report@https://brandessenceresearch.com/downloadSample/PostId/273 Elaborating the Key Trends and Dynamics of Wireless Brain Sensor Market The growing occurrence of neurological disorders, increased instances of traumatic brain injuries, and rising healthcare expenditure are primarily augmenting the outlook of this business...
PR Newswire
30/05/2023
Altri  Comunicati